Mark Schoenebaum Net Worth

What's Mark Schoenebaum's mailing address?

Mark's mailing address filed with the SEC is 787 SEVENTH AVENUE, 48TH FLOOR, NEW YORK, NY, 10019.

Insiders trading at TG Therapeutics Inc

Over the last 12 years, insiders at TG Therapeutics Inc have traded over $23,556,837 worth of TG Therapeutics Inc stock and bought 549,710 units worth $3,334,566 . The most active insiders traders include Capital Management, L.P.Kol..., Michael S Weiss, and Sean A Power. On average, TG Therapeutics Inc executives and independent directors trade stock every 107 days with the average trade being worth of $1,103,023. The most recent stock trade was executed by Sagar Lonial on 17 June 2024, trading 25,933 units of TGTX stock currently worth $432,822.

What does TG Therapeutics Inc do?

tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".

TG Therapeutics Inc executives and stock owners

TG Therapeutics Inc executives and other stock owners filed with the SEC include:

• Michael Weiss,
  Executive Chairman of the Board, President, Chief Executive Officer
• Michael S. Weiss Esq.,
  Chairman, CEO & Pres
• Sean Power,
  Chief Financial Officer, Treasurer, Corporate Secretary
• Sean A. Power CPA, CPA,
  CFO, Corp. Sec. & Treasurer
• Laurence Charney,
  Independent Director
• Kenneth Hoberman,
  Independent Director
• William Kennedy,
  Independent Director
• Daniel Hume,
  Independent Director
• Yann Echelard,
  Independent Director
• Jenna Bosco,
  Senior Vice President - Corporate Communications
• Sagar Lonial,
  Independent Director
• Kelly Ross,
  Chief Technology Officer
• Adam Waldman,
  Chief Commercial Officer
• Dr. Owen A. O'Connor,
  Chief Scientific Officer
• Biotechnologies S.A.S.U. Lfb,
  10% owner
• Mark Schoenebaum,
  Director
• Neil Herskowitz,
  Director
• Capital Management, L.P.Kol...,